NCT00090207View on ClinicalTrials.gov

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

PHASE4CompletedINTERVENTIONAL

Enrollment

477

Participants

Timeline

Start Date

January 13, 2004

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2004

Conditions

NauseaVomiting

Interventions

DRUG

MK0869, aprepitant / Duration of Treatment: 3 days

DRUG

Comparator: ondansetron / Duration of Treatment: 4 days

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00090207 - Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED) | Biotech Hunter | Biotech Hunter